{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:52:52Z","timestamp":1794610372409,"version":"4.9.1"},"reference-count":119,"publisher":"American Association for Cancer Research (AACR)","issue":"8","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA184770"],"award-info":[{"award-number":["R01CA184770"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mike Slive Prostate Cancer Foundation","id":[{"id":"https:\/\/ror.org\/01npwtv09","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapeutic interventions to harness the immune system against tumor cells have provided mixed results in the past for several solid tumors and hematologic malignancies. However, immunotherapy has advanced considerably over the last decade and is becoming an integral combination for treating patients with advanced solid tumors. In particular, prostate cancer immunotherapy has shown modest efficacy for patients in the past. With several key discoveries on immune mechanisms and advanced molecular diagnostic platforms recently, immunotherapy is re-emerging as a viable option for prostate cancer, especially castration-resistant prostate cancer (CRPC), to stimulate antitumor immunity. Combination of patient-tailored immunotherapy and immune checkpoint blockers with conventional cytotoxic agents and androgen receptor\u2013targeted therapies should move the field forward. With a recent adaptation that the application of immune checkpoint inhibitors has been successful in the treatment of more than a dozen solid tumors, including melanoma, lymphoma, liver, cervical, gastrointestinal, and breast cancers, it is a timely endeavor to harness immunotherapy for prostate cancer. Here, we provide an account on the progression of immunotherapy with new discoveries and precision approaches for tumors, in particular CRPC, from mechanistic standpoint to emerging limitations and future directions.<\/jats:p>","DOI":"10.1158\/0008-5472.can-19-2948","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T14:35:14Z","timestamp":1581950114000},"page":"1615-1623","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":207,"title":["Revisiting Immunotherapy: A Focus on Prostate Cancer"],"prefix":"10.1158","volume":"80","author":[{"given":"Ha-Ram","family":"Cha","sequence":"first","affiliation":[{"name":"1Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama."},{"name":"2McWhorter School of Pharmacy, Samford University, Birmingham, Alabama."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4450-3067","authenticated-orcid":false,"given":"Joo Hyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"1Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama."},{"name":"3PharmAbcine Inc., Yuseong-gu Daejeon, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvarangan","family":"Ponnazhagan","sequence":"additional","affiliation":[{"name":"1Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"2022061706280315900_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2022061706280315900_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","article-title":"Advances in cancer immunotherapy 2019 - latest trends","volume":"38","author":"Kruger","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"2022061706280315900_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-3-319-95693-0_3","article-title":"Inflammation and prostate cancer","volume":"1095","author":"Tewari","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"2022061706280315900_bib4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1055-9965.EPI-13-1126","article-title":"Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial","volume":"23","author":"Gurel","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022061706280315900_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2559.2011.04033.x","article-title":"Prostate cancer and inflammation: the evidence","volume":"60","author":"Sfanos","year":"2012","journal-title":"Histopathology"},{"key":"2022061706280315900_bib6","first-page":"3","article-title":"Infections and inflammation in prostate cancer","volume":"1","author":"Sfanos","year":"2013","journal-title":"Am J Clin Exp Urol"},{"key":"2022061706280315900_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20153833","article-title":"Current knowledge of the potential links between inflammation and prostate cancer","volume":"20","author":"Cai","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2022061706280315900_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1078-0432.CCR-14-1520","article-title":"The high-dose aldesleukin \"select\" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma","volume":"21","author":"McDermott","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2022061706280315900_bib9","doi-asserted-by":"crossref","first-page":"e1163462","DOI":"10.1080\/2162402X.2016.1163462","article-title":"Role of IL-2 in cancer immunotherapy","volume":"5","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"key":"2022061706280315900_bib10","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent","volume":"8","author":"Wang","year":"2017","journal-title":"Nat Commun"},{"key":"2022061706280315900_bib11","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-17-1365","article-title":"T-cell homing therapy for reducing regulatory T cells and preserving effector T-cell function in large solid tumors","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2022061706280315900_bib12","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"2022061706280315900_bib13","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in cancer immunotherapy","volume":"10","author":"Waldmann","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2022061706280315900_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1634\/theoncologist.11-4-397","article-title":"TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility","volume":"11","author":"van Horssen","year":"2006","journal-title":"Oncologist"},{"key":"2022061706280315900_bib15","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"2022061706280315900_bib16","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2019.37.15_suppl.2509","article-title":"Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma","volume":"37","author":"Zhan X","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022061706280315900_bib17","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"2022061706280315900_bib18","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"2022061706280315900_bib19","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2022061706280315900_bib20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"2022061706280315900_bib21","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"2022061706280315900_bib22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.molmed.2012.04.009","article-title":"CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe","volume":"18","author":"Gilham","year":"2012","journal-title":"Trends Mol Med"},{"key":"2022061706280315900_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/pros.22749","article-title":"Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy","volume":"74","author":"Ma","year":"2014","journal-title":"Prostate"},{"key":"2022061706280315900_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","article-title":"Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment","volume":"25","author":"Gajewski","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"2022061706280315900_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","article-title":"Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies","volume":"31","author":"Anderson","year":"2017","journal-title":"Cancer Cell"},{"key":"2022061706280315900_bib26","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"key":"2022061706280315900_bib27","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.cell.2017.04.016","article-title":"An immune atlas of clear cell renal cell carcinoma","volume":"169","author":"Chevrier","year":"2017","journal-title":"Cell"},{"key":"2022061706280315900_bib28","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.13895","article-title":"PD-1 and its ligands are important immune checkpoints in cancer","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"key":"2022061706280315900_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"2022061706280315900_bib30","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","article-title":"Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer","volume":"19","author":"Tagawa","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022061706280315900_bib31","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.32072","article-title":"Phase 1\/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer","volume":"125","author":"Tagawa","year":"2019","journal-title":"Cancer"},{"key":"2022061706280315900_bib32","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.18.01927","article-title":"Strategies for evaluation of novel imaging in prostate cancer: putting the horse back before the cart","volume":"37","author":"Vapiwala","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022061706280315900_bib33","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3389\/fonc.2018.00653","article-title":"New prostate cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen","volume":"8","author":"Cimadamore","year":"2018","journal-title":"Front Oncol"},{"key":"2022061706280315900_bib34","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"Grubmuller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2022061706280315900_bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrclinonc.2015.95","article-title":"Gynaecological cancer: biomarker potential of CA-125 enhanced","volume":"12","author":"Killock","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061706280315900_bib36","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000342164","article-title":"Tumor-associated antigens in breast cancer","volume":"7","author":"Criscitiello","year":"2012","journal-title":"Breast Care"},{"key":"2022061706280315900_bib37","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/gut.52.suppl_3.iii1","article-title":"Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults","volume":"52","author":"Ryder","year":"2003","journal-title":"Gut"},{"key":"2022061706280315900_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceb.2015.08.002","article-title":"The MAGE protein family and cancer","volume":"37","author":"Weon","year":"2015","journal-title":"Curr Opin Cell Biol"},{"key":"2022061706280315900_bib39","first-page":"197","article-title":"Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer","volume":"36","author":"Anassi","year":"2011","journal-title":"P T"},{"key":"2022061706280315900_bib40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"2022061706280315900_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8070064","article-title":"A perspective of immunotherapy for prostate cancer","volume":"8","author":"Silvestri","year":"2016","journal-title":"Cancers"},{"key":"2022061706280315900_bib42","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","article-title":"Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial","volume":"81","author":"Schellhammer","year":"2013","journal-title":"Urology"},{"key":"2022061706280315900_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/ITT.S122497","article-title":"Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer","volume":"6","author":"Scholz","year":"2017","journal-title":"Immunotargets Ther"},{"key":"2022061706280315900_bib44","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley J","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022061706280315900_bib45","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022061706280315900_bib46","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-17-0807","article-title":"Expression of PD-L1 in hormone-naive and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide","volume":"23","author":"Calagua","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022061706280315900_bib47","first-page":"e65","article-title":"Immunotherapy for prostate cancer: where do we go from here?-PART 2: checkpoint inhibitors, immunotherapy combinations, tumor microenvironment modulation, and cellular therapies","volume":"32","author":"Patel","year":"2018","journal-title":"Oncology"},{"key":"2022061706280315900_bib48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/pcan.2015.39","article-title":"Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance","volume":"18","author":"Martin","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2022061706280315900_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/B978-0-12-394299-9.00007-2","article-title":"Active and passive anticytokine immune therapies: current status and development","volume":"115","author":"Le Buanec","year":"2012","journal-title":"Adv Immunol"},{"key":"2022061706280315900_bib50","first-page":"4105","article-title":"Present and future of cancer immunotherapy: a tumor microenvironmental perspective","volume":"16","author":"Yu","year":"2018","journal-title":"Oncol Lett"},{"key":"2022061706280315900_bib51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"2022061706280315900_bib52","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"2022061706280315900_bib53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2022061706280315900_bib54","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"2022061706280315900_bib55","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2022061706280315900_bib56","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"2022061706280315900_bib57","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"2022061706280315900_bib58","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2022061706280315900_bib59","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41389-017-0013-7","article-title":"Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy","volume":"7","author":"Cheng","year":"2018","journal-title":"Oncogenesis"},{"key":"2022061706280315900_bib60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2022061706280315900_bib61","doi-asserted-by":"crossref","first-page":"4861570","DOI":"10.1155\/2017\/4861570","article-title":"Immunotherapy as a promising treatment for prostate cancer: a systematic review","volume":"2017","author":"Janiczek","year":"2017","journal-title":"J Immunol Res"},{"key":"2022061706280315900_bib62","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/cas.13932","article-title":"KEYNOTE-025: phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer","volume":"110","author":"Nishio","year":"2019","journal-title":"Cancer Sci"},{"key":"2022061706280315900_bib63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2022061706280315900_bib64","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2022061706280315900_bib65","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"2022061706280315900_bib66","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1200\/JCO.2019.37.7_suppl.216","article-title":"Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: updated analysis of KEYNOTE-199","volume":"27","author":"Antonarakis","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022061706280315900_bib67","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1200\/JCO.2017.35.6_suppl.159","article-title":"Avelumab in metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"Fakhrejahani","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022061706280315900_bib68","doi-asserted-by":"crossref","first-page":"11472","DOI":"10.1038\/s41598-019-47910-1","article-title":"Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling","volume":"9","author":"De Sousa Linhares","year":"2019","journal-title":"Sci Rep"},{"key":"2022061706280315900_bib69","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/cr.2015.3","article-title":"Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25","volume":"25","author":"Hannani","year":"2015","journal-title":"Cell Res"},{"key":"2022061706280315900_bib70","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022061706280315900_bib71","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"key":"2022061706280315900_bib72","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2019.37.7_suppl.142","article-title":"Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650)","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022061706280315900_bib73","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1158\/2159-8290.CD-NB2019-039","article-title":"Anti-PD-1-CTLA4 combo hits prostate cancer","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"key":"2022061706280315900_bib74","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"2022061706280315900_bib75","doi-asserted-by":"crossref","first-page":"17796","DOI":"10.1073\/pnas.1316026110","article-title":"Bispecific small molecule-antibody conjugate targeting prostate cancer","volume":"110","author":"Kim","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706280315900_bib76","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1016\/j.bmcl.2017.09.065","article-title":"PSMA-targeted bispecific Fab conjugates that engage T cells","volume":"27","author":"Patterson","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"2022061706280315900_bib77","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1158\/1535-7163.MCT-15-0242","article-title":"MOR209\/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer","volume":"15","author":"Hernandez-Hoyos","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2022061706280315900_bib78","doi-asserted-by":"crossref","first-page":"285193","DOI":"10.1155\/2015\/285193","article-title":"Phase I study of anti-CD3 x anti-Her2 bispecific antibody in metastatic castrate resistant prostate cancer patients","volume":"2015","author":"Vaishampayan","year":"2015","journal-title":"Prostate Cancer"},{"key":"2022061706280315900_bib79","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","article-title":"An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells","volume":"78","author":"Freedman","year":"2018","journal-title":"Cancer Res"},{"key":"2022061706280315900_bib80","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2019.37.15_suppl.5034","article-title":"Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"37","author":"Hummel","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022061706280315900_bib81","doi-asserted-by":"crossref","first-page":"E856","DOI":"10.1152\/ajpendo.00484.2005","article-title":"Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and\/or its metabolites","volume":"290","author":"Page","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022061706280315900_bib82","doi-asserted-by":"crossref","first-page":"T297","DOI":"10.1530\/ERC-17-0145","article-title":"Androgen deprivation and immunotherapy for the treatment of prostate cancer","volume":"24","author":"Gamat","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"2022061706280315900_bib83","doi-asserted-by":"crossref","first-page":"9887","DOI":"10.1073\/pnas.1402468111","article-title":"Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation","volume":"111","author":"Kissick","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706280315900_bib84","doi-asserted-by":"crossref","first-page":"333ra47","DOI":"10.1126\/scitranslmed.aad5659","article-title":"Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse","volume":"8","author":"Pu","year":"2016","journal-title":"Sci Transl Med"},{"key":"2022061706280315900_bib85","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1158\/1078-0432.CCR-07-5048","article-title":"Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy","volume":"14","author":"Madan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061706280315900_bib86","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur J Cancer"},{"key":"2022061706280315900_bib87","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/jnci\/djy145","article-title":"Finding an immunologic beachhead in the prostate cancer microenvironment","volume":"111","author":"Madan","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2022061706280315900_bib88","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1002\/1097-0142(20011215)92:12<2985::AID-CNCR10175>3.0.CO;2-5","article-title":"Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma","volume":"92","author":"Shariat","year":"2001","journal-title":"Cancer"},{"key":"2022061706280315900_bib89","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.4049\/jimmunol.177.10.7398","article-title":"CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients","volume":"177","author":"Miller","year":"2006","journal-title":"J Immunol"},{"key":"2022061706280315900_bib90","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/1078-0432.CCR-07-2056","article-title":"Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer","volume":"14","author":"Yokokawa","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061706280315900_bib91","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.4049\/jimmunol.0803400","article-title":"Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells","volume":"182","author":"Getnet","year":"2009","journal-title":"J Immunol"},{"key":"2022061706280315900_bib92","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","article-title":"Myeloid-derived suppressor cells: linking inflammation and cancer","volume":"182","author":"Ostrand-Rosenberg","year":"2009","journal-title":"J Immunol"},{"key":"2022061706280315900_bib93","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2022061706280315900_bib94","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.clgc.2017.04.002","article-title":"Immune characterization of the programmed death receptor pathway in high risk prostate cancer","volume":"15","author":"Baas","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2022061706280315900_bib95","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jnci\/djy141","article-title":"The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target","volume":"111","author":"Zhao","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2022061706280315900_bib96","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.ajpath.2018.02.014","article-title":"Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer","volume":"188","author":"Haffner","year":"2018","journal-title":"Am J Pathol"},{"key":"2022061706280315900_bib97","doi-asserted-by":"crossref","first-page":"234","DOI":"10.18632\/oncotarget.2703","article-title":"PD-L1 is highly expressed in Enzalutamide resistant prostate cancer","volume":"6","author":"Bishop","year":"2015","journal-title":"Oncotarget"},{"key":"2022061706280315900_bib98","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J Clin Invest"},{"key":"2022061706280315900_bib99","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.3389\/fimmu.2019.01856","article-title":"Mutation-derived neoantigens for cancer immunotherapy","volume":"10","author":"Castle","year":"2019","journal-title":"Front Immunol"},{"key":"2022061706280315900_bib100","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.eururo.2018.08.009","article-title":"Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity","volume":"75","author":"Lovf","year":"2019","journal-title":"Eur Urol"},{"key":"2022061706280315900_bib101","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/pros.23914","article-title":"Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue","volume":"80","author":"Lu","year":"2020","journal-title":"Prostate"},{"key":"2022061706280315900_bib102","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.celrep.2019.07.073","article-title":"Structure and functional binding epitope of V-domain Ig suppressor of T cell activation","volume":"28","author":"Mehta","year":"2019","journal-title":"Cell Rep"},{"key":"2022061706280315900_bib103","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"key":"2022061706280315900_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for naive T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"key":"2022061706280315900_bib105","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1073\/pnas.1908711117","article-title":"Structural insight into T cell coinhibition by PD-1H (VISTA)","volume":"117","author":"Slater","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706280315900_bib106","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.ajpath.2012.07.008","article-title":"Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice","volume":"181","author":"Lai","year":"2012","journal-title":"Am J Pathol"},{"key":"2022061706280315900_bib107","doi-asserted-by":"crossref","first-page":"98598","DOI":"10.18632\/oncotarget.21985","article-title":"Cell surface Thomsen-Friedenreich proteome profiling of metastatic prostate cancer cells reveals potential link with cancer stem cell-like phenotype","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"2022061706280315900_bib108","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1158\/0008-5472.CAN-09-3806","article-title":"High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer","volume":"70","author":"van den Hoogen","year":"2010","journal-title":"Cancer Res"},{"key":"2022061706280315900_bib109","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/imm.12866","article-title":"Cancer stem cells as targets for immunotherapy","volume":"153","author":"Codd","year":"2018","journal-title":"Immunology"},{"key":"2022061706280315900_bib110","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2022061706280315900_bib111","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1158\/1078-0432.CCR-13-2116","article-title":"Intratumoral immunization: a new paradigm for cancer therapy","volume":"20","author":"Marabelle","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022061706280315900_bib112","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022061706280315900_bib113","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"2022061706280315900_bib114","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-14-3510","article-title":"Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-\/-IL2Rgammanull immunodeficient mice","volume":"75","author":"Sanmamed","year":"2015","journal-title":"Cancer Res"},{"key":"2022061706280315900_bib115","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/pros.23155","article-title":"Prostate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages","volume":"76","author":"Cha","year":"2016","journal-title":"Prostate"},{"key":"2022061706280315900_bib116","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/pros.21282","article-title":"LL-37 as a therapeutic target for late stage prostate cancer","volume":"71","author":"Hensel","year":"2011","journal-title":"Prostate"},{"key":"2022061706280315900_bib117","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1200\/JCO.2019.37.4_suppl.TPS465","article-title":"A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) \u00b1 chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC)","volume":"37","author":"Wang-Gillam","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022061706280315900_bib118","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1073\/pnas.1417660112","article-title":"Endostatin: a novel inhibitor of androgen receptor function in prostate cancer","volume":"112","author":"Lee","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706280315900_bib119","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1096\/fj.201601178R","article-title":"Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress","volume":"31","author":"Lee","year":"2017","journal-title":"FASEB J"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/8\/1615\/2803309\/1615.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/8\/1615\/2803309\/1615.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T14:43:44Z","timestamp":1655477024000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/80\/8\/1615\/647795\/Revisiting-Immunotherapy-A-Focus-on-Prostate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":119,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,4,15]]},"published-print":{"date-parts":[[2020,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-19-2948","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]}}}